Outsourcing Pharmaceutical Infrastructure Operations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing Pharmaceutical Infrastructure Operations
Key considerations for outsourcing energy services.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 56-58

Leveraging combined heat and power


Figure 1: Comparison of separate heat and power generation with cogeneration. (FIGURE IS COURTESY OF THE AUTHORS)
Another key advantage of outsourcing energy management is that full-service outside providers possess the expertise to evaluate, design, build, and then operate technologies such as combined heat and power (CHP) to optimize energy efficiency. CHP, sometimes referred to as cogeneration, is an efficient energy technology that simultaneously generates power (i.e., electricity) and thermal energy, which is used for heating, cooling, and production of high-pressure process steam, while typically consuming only 60% of the fuel required for separate processes (1). Figure 1 illustrates the higher energy efficiency of CHP compared to separate heat and power production. CHP technology is currently experiencing a resurgence in pharmaceutical facilities due to its many operational benefits. CHP can provide increased energy reliability, greater fuel flexibility, and market responsiveness. CHP can also mitigate lost products and research projects due to utility grid failures. CHP reduces greenhouse gas emissions; the waste heat generated during the power production process can be captured, recycled, and used for process applications without the need for boilers within each building.

CHP is a proven solution for industrial manufacturing environments, in which reliable power is crucial. According to the US Environmental Protection Agency's (EPA) Combined Heat and Power Partnership, 88% of existing CHP plants are utilized for industrial purposes (2). The other 12% are used by commercial and institutional entities such as hospitals, municipal and state governments, colleges, and universities. With a full-service outsourcing provider, designing, building, and operating complex energy infrastructure may be achieved seamlessly.

Customers that implement CHP typically experience the following benefits:
  • Cost savings. Burning less fuel generates cost savings. CHP users avoid buying from the market at peak price periods. CHP can also be configured to use locally-sourced renewable fuels.
  • Reliability. Utility power outages will not interrupt CHP operations, so critical processes continue uninterrupted.
  • Environmental benefits. Greenhouse gas emissions and criteria air pollutants are reduced when less fuel is combusted.
  • Fuel diversity. CHP plants may be designed for input of multiple sources of fuel. This multi-fuel ability increases energy security and can also mitigate volatility in fuel commodity prices.

Conclusion

Outsourcing may seem like a simple concept, but the potential benefits are significant, especially when complex energy infrastructure must be operated and maintained at the highest levels of reliability. Pharmaceutical research and manufacturing processes are costly to operate, so outsourcing the facility's energy plant operations and management can be a solution to control costs, reduce fuel and energy consumption, and evaluate and implement energy solutions and technologies that can ensure the integrity of the underlying processes.

Mel Palmer is business development director for Veolia Energy North America,
, tel. 617.849.6656. David Lyons is client operations manager at Dalkia Ireland's Pharmaceutical & Healthcare division.

References

1. EPA, "Efficiency Benefits," http://www.epa.gov/chp/basic/efficiency.html, accessed June 20, 2012.

2. EPA, "Combined Heat and Power FAQ," http://www.epa.gov/chp/documents/faq.pdf, accessed June 22, 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
43%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here